D.
Roke
,
M.
Fañanás-Mastral§
* and
B. L.
Feringa
*
Stratingh Institute for Chemistry, University of Groningen, Nijenborg 4, 9747 AG Groningen, Netherlands. E-mail: B.L.Feringa@rug.nl
First published on 7th July 2016
Polypropionate fragments are synthesized using a combination of a copper-catalyzed asymmetric allylic alkylation, ruthenium-catalyzed cross-metathesis and iridium-catalyzed asymmetric allylic etherification. The use of an appropriate chiral ligand for each catalytic reaction allows access to 1,2-hydroxymethyl arrays with good to excellent control over the relative and absolute configuration of the different stereocenters.
![]() | ||
| Fig. 1 (a) Examples of polyketides bearing polypropionate segments (highlighted in red). (b) Three configurations of polypropionate segments described in this paper. | ||
Polypropionates consist of alternating methyl- and hydroxyl-substituted stereocenters. The combination of these two different motifs leads to a large number of possible distinct stereochemical combinations. The importance of these complex chemical structures has directed a lot of attention towards the diastereoselective and enantioselective synthesis of polypropionates.4 In an attempt to mimic the biosynthetic pathway, the stereoselective aldol reaction is arguably the most extensively studied method.5,6 However, a large number of highly successful alternative approaches has been reported such as crotylations,7 reductive aldol couplings8 and epoxide ring-opening reactions.9 Important methods for the asymmetric synthesis of polypropionates frequently start with stoichiometric amounts of chiral materials, either from natural sources or often in the form of chiral auxiliaries which are to be attached and cleaved off in separate steps.
A growing number of catalytic methods towards polypropionates are emerging,4 and examples include (organo)catalytic aldol couplings,5,10 reductive aldol couplings4,8,11 and catalytic crotylations.12 Although already a variety of useful catalytic asymmetric methods towards chiral propionate units exists, most of these methods have been limited due to the fact that only one 1,2-hydroxymethyl moiety is introduced,10–12 making it difficult to perform these methods iteratively to allow the formation of polypropionates.
The transition metal-catalyzed asymmetric allylic substitution is a widely investigated reaction, which allows the formation of C–C, C–H, C–S, C–N and C–O bonds in a highly enantioselective manner.13 In particular, the SN2′-selective allylic substitution provides a versatile substrate which bears a stereocenter next to a double bond which can be further functionalized.13,14 Copper-catalyzed asymmetric allylic alkylations with organometallic reagents usually proceed with high SN2′ selectivity being a powerful tool for the construction of optically active carbon stereocenters.15 A wide range of chiral ligands has been utilized for the copper-catalyzed asymmetric allylic alkylation, examples include phosphoramidites,16 diphosphines,17 phosphine–phosphite18 and NHC ligands.19 Among these different catalytic systems, the combination of CuBr·SMe2 with Taniaphos L1 has emerged as an excellent catalyst for the introduction of the methyl unit via copper-catalyzed AAA.17
On the other hand different transition metals have been employed for the asymmetric allylic C–O bond formation towards branched allyl ethers and alcohols.20–28 Among these systems Ir/phosphoramidite complexes have emerged as very efficient catalysts for SN2′-selective asymmetric allylic etherification.13d,f,g,23–27 Substitutions with phenoxides23 and alkoxides24a,b and alcohols24c have been shown to provide excellent results. Moreover silanoates25 and caboxylates26 can be introduced and even a direct hydroxylation using carbonates as pronucleophiles has been reported.27
An iterative approach, in which the methyl and hydroxyl substituents are introduced in separate allylic substitution steps, could be a potentially powerful approach towards polypropionates. A related strategy has been used before for the synthesis of 1,2-dihydroxy arrays23e,28 and, albeit non-iteratively, for 1,2-aminoethyl arrays.29 However for polypropionates only a few sequential approaches have been published,30 and to the best of our knowledge a catalytic iterative approach in which alternating methyl and hydroxyl groups are sequentially introduced to arrive at the distinct diastereomers and enantiomers of polypropionates has not been reported.4 A distinct advantage of such a catalytic iterative approach is that it can be performed in a diastereodivergent way, in which the diastereoselectivity is controlled fully by the chiral catalyst.
Herein we present an iterative catalytic method for the synthesis of polypropionates in which stereocenters are sequentially generated using a copper-catalyzed asymmetric allylic alkylation, reported earlier by our group,17f in combination with an iridium-catalyzed asymmetric allylic etherification (Scheme 1).23d,e The combination of subsequent asymmetric allylic substitution reactions allows for the sequential introduction of methyl- and hydroxyl-substituted stereocenters. Control over the distinct configurations was achieved by the use of an appropriate enantiomer of the chiral ligand to obtain the desired stereochemistry. After each new stereocenter that is introduced by a catalytic allylic substitution, a ruthenium-catalyzed cross-metathesis is performed to introduce either an allylic carbonate or allylic bromide to allow the next stereocenter to be introduced.
:
1; syn dr = 90
:
10, Scheme 2).17f Both the syn- and anti-isomers of product 2 can be obtained by choosing the appropriate enantiomer of the Taniaphos ligand L1. The pure syn-2b diastereomer was readily obtained by column chromatography. The configuration of the newly formed stereocenter is determined largely by the chiral catalyst, rather than the chirality present in the substrate, indicating a high level of catalyst control. Protecting the adjacent allylic hydroxyl using a dioxolane ring appeared to be essential, since other protecting groups gave rather low conversion and/or regioselectivity.17f
![]() | ||
Scheme 2 Asymmetric allylic alkylations of allyl bromide 1 towards products 2. a Diastereomeric ratio (dr) determined by GC-MS analysis. | ||
Next, both anti- and syn-products 2 were converted into the corresponding allyl carbonates 4 by a cross-metathesis reaction. Using a Hoveyda–Grubbs 2nd generation catalyst and the readily available (Z)-but-2-ene-1,4-diyl bis(4-methoxyphenyl) dicarbonate (3, Scheme 3), carbonates 4a and 4b were obtained in 69% and 66% yield, respectively.
In the next step we explored the iridium-catalyzed asymmetric allylic etherification giving products 5 bearing a 1,3-hydroxy-2-methyl unit, featuring three contiguous stereocenters (Scheme 4). A wide range of different methods for asymmetric allylic alkylations using O-nucleophiles have been reported, often giving rise to allylic ethers with excellent regio- and enantioselectivity.20,21,23–27 Our attention was drawn by one specific method reported by Han and coworkers, in which decarboxylative allylic etherification was performed, to provide branched allylic para-methoxyphenyl ethers (–OPMP).23d,e In contrast to the previous asymmetric allylic etherifications, this method does not require the use of an external nucleophile, leading to a higher atom efficiency. Moreover, the para-methoxyphenyl ethers are generally easily cleaved under oxidative conditions to liberate the free hydroxyl moiety.31
![]() | ||
Scheme 4 Asymmetric allylic etherifications of allyl carbonates 4 forming allyl ethers 5. a Diastereomeric ratio determined by GC-MS and 1H-NMR analysis of the crude product. | ||
Performing the etherification, using [Ir(dbcot)Cl]2
32 in the presence of chiral phosphoramidite ligand L2 and DBU as a base in THF (Scheme 4), resulted in high conversion towards the allylic ethers 5. To our delight, when we applied Han's conditions to allylic carbonate 4a with (S,S,S)-L2, anti–anti isomer 5a was obtained with excellent diastereoselectivity. When the opposite enantiomer (R,R,R)-L2 was used, substrate 4a was converted into anti–syn-isomer 5b. A diastereomeric ratio of over 20
:
1 was found, showing no obvious mismatch effect. Finally, when the asymmetric allylic etherification was performed on substrate 4b using ligand (S,S,S)-L2, syn–syn-isomer 5c was obtained, again with excellent control over diastereoselectivity, with a diastereomeric ratio of over 20
:
1. Moreover, in all cases, the control over regioselectivity is perfect, as no linear product due to SN2 substitution was observed.
To highlight the potential iteration of our method, allyl bromides 7 were synthesized to perform a second copper-catalyzed asymmetric allylic alkylation. The terminal olefin was converted into the required allylic bromide necessary for the subsequent alkylation using a challenging cross-metathesis reaction (Scheme 5).33 Substrates 5a and 5b were converted into the allylic bromides 7a and 7b, respectively, with (E)-1,4-dibromo-2-butene (6) applying the Hoveyda–Grubbs 2nd generation catalyst. Allylic bromides 7a and 7b were obtained in 81% and 64% yield, respectively.34
![]() | ||
Scheme 5 Cross-metathesis reactions to convert the terminal olefins into allylic bromides. a Yields are based on the recovered starting material. | ||
A second methyl substituent was introduced via a copper-catalyzed asymmetric allylic alkylation, creating a molecule bearing four consecutive stereocenters (Scheme 6). When we subjected substrates 7 to our previously optimized conditions for the copper-catalyzed asymmetric allylic alkylation of substrate 1, high selectivity was obtained, and rather low conversion was observed. Therefore, a screening of temperatures, copper complexes and ligands was performed on a model substrate (see the ESI‡), showing that none of the tested systems gave better selectivity than our initial system consisting of CuBr·SMe2 and Taniaphos ligand L1. However, using this catalyst system, high conversion could be obtained by raising the temperature to −60 °C. When we subjected allylic bromide 7a to these newly optimized conditions using (R,R)-Taniaphos L1, nearly full conversion and high selectivities in the allylic alkylation towards product 8a with the anti–anti–anti configuration were obtained. This configuration has shown to be the most challenging stereochemical array to synthesize via conventional methods.4d,35 Remarkably, the increase in temperature from −80 °C to −60 °C compared to the asymmetric allylic alkylation of substrate 1 did not affect the SN2′
:
SN2 ratio. Studies on copper-catalyzed asymmetric allylic alkylations of related structures bearing a vicinal stereocenter are very scarce. Notably, a recent study from our group showed that low regioselectivity is obtained with related substrates with other protecting groups at the allylic alcohol unit.17f Apart from this, as far as we know only a kinetic resolution of allylic substrates bearing an alkyl substituent at the allylic stereocenter has been published.36
Product 8b with the anti–syn–anti-configuration was obtained with excellent selectivities and high conversion, although prolonged reaction times and increased catalyst loading are needed. Even though the configuration of the newly introduced substituent in products 8a and 8b is both anti with respect to the vicinal stereocenter, it is clear that the reaction towards product 8a proceeds faster (1 d versus 3 d) and with a lower catalyst loading (5 mol% versus 7.5 mol%). In this case it seems that the interaction with the more remote stereocenter (1,3-methyl–methyl interaction) has a rather large influence on the reactivity and that the 1,3-syn-configuration in product 8a is preferred over the 1,3-anti-configuration in product 8b. A similar effect was observed in the synthesis of deoxypropionates reported by Hanessian and coworkers and it was hypothesized that syn-pentane interactions37 would be minimized in the CuIII-intermediate when the methyl and CuIII-complex are syn to each other, leading to the syn-product (Fig. 2).38 When these substituents are anti to each other (leading to anti-products), these interactions are maximized. It is however not clear what the effect of the bulky –OPMP substituent is and how this changes the 1,3-interaction.
![]() | ||
| Fig. 2 syn-Pentane interactions of 1,3-dimethyl moieties in a diamond lattice. Ligands on copper are not presented for clarification. | ||
The new protocol presented here was also effective for the even more challenging methylation towards the anti–anti–syn-8c stereoisomer. In this case, the methyl unit that had to be introduced is syn with respect to the vicinal stereocenter already present. As shown for substrate 1, a mismatch effect is expected due to unfavorable steric interactions of the substrate with the catalyst when a methyl substituent is introduced with a 1,2-syn-configuration. Moreover, also the 1,3-methyl–methyl interactions are unfavorable, making this diastereomer the most difficult one to access. Despite the highly unfavorable interactions, high regioselectivity (b
:
l > 11
:
1) was observed towards product 1,2-syn-8c when we subjected substrate 7a to our reaction conditions, using (S,S)-Taniaphos L1. Although a slightly reduced stereoselectivity was observed in this case, most probably arising from competing substrate control, the anti–anti–syn isomer 8c could still be obtained with good selectivity (dr = 4
:
1). It is important to note that the small amount of minor stereoisomer was readily removed by column chromatography to provide product 8c as a single enantiomer in 50% yield.
To overcome the mismatch effect observed in the allylic alkylation towards product syn-8c which resulted in a decrease in diastereoselectivity, an alternative approach was studied. In previous work, we showed that the presence of the dioxolane ring is essential to obtain high selectivity in an asymmetric allylic alkylation towards 1,2-hydroxymethyl units.17f We envisioned that installing a dioxane ring in our system might also improve the stereoselectivity. A sequence consisting of deprotection–protection steps starting from 5a afforded olefin 9 in 59% overall yield (Scheme 7). Next, a ruthenium-catalyzed cross-metathesis was performed with (E)-1,4-dibromo-2-butene and the Hoveyda–Grubbs 2nd generation catalyst to provide allylic bromide 10.
This adapted strategy was highly rewarding as the copper-catalyzed asymmetric allylic alkylation of allylic bromide 10 shows that excellent stereoselectivity and regioselectivity are obtained towards product 11 (Scheme 8). Product 11 has the same anti–anti–syn configuration as product 8c, but shows a near perfect degree of stereocontrol, likely due to the protection of the hydroxyl moiety as part of the dioxane ring. Although this reaction suffers from rather low conversion, starting materials can be readily recovered and resubjected to the reaction. These results show that the three polypropionate segments bearing anti–anti–anti, anti–syn–anti and anti–anti–syn stereochemical units can be obtained in a catalytic iterative manner with branched linear and diastereomeric ratios of over 95
:
5.
![]() | ||
| Scheme 8 Copper-catalyzed asymmetric allylic alkylation towards product 11. Conversion, diastereomeric ratio and branched to linear ratio are based on the 1H-NMR analysis of the crude product. | ||
:
1) afforded 4a (65.5 mg, 69%) as a colorless oil. [α]20D = −2.4° (c = 1.0 in CHCl3). 1H NMR (400 MHz, CDCl3): δ 7.09 (m, 2H), 6.88 (m, 2H), 5.91 (dd, J = 7.1, 15.6 Hz, 1 H), 5.71 (dt, J = 15.6, 6.5 Hz, 1H), 4.71 (m, 2H), 3.99 (m, 2H), 3.80 (s, 3H), 3.63 (dd, J = 6.1, 13.3 Hz, 1H), 1.41 (s, 1H), 1.36 (s, 1H), 1.03 (d, J = 6.9 Hz, 3H). 13C NMR (101 MHz, CDCl3): δ 157.4, 153.9, 144.7, 138.4, 123.5, 121.9, 114.4, 109.1, 79.1, 69.1, 67.4, 55.6, 39.5, 26.5, 25.5, 15.6. HRMS (ESI+, m/z): Calcd for C18H25O6 [M + H+]: 337.1641, found: 337.1646.
:
1) afforded 4b (136.9 mg, 66%) as a colorless oil. [α]20D = +15.2° (c = 1.0 in CHCl3). 1H NMR (400 MHz, CDCl3): δ 7.09 (m, 2H), 6.88 (m, 2H), 5.74 (m, 2H), 4.67 (d, J = 5.3 Hz, 2H), 3.94 (m, 2H), 3.79 (s, 3H), 3.64 (m, 1H), 2.39 (m, 1H), 1.41 (s, 1H), 1.35 (s, 1H), 1.11 (d, J = 6.8 Hz, 3H). 13C NMR (101 MHz, CDCl3): δ 157.4, 153.9, 144.7, 137.8, 124.0, 121.8, 114.4, 109.1, 79.1, 68.9, 67.4, 55.6, 40.3, 26.7, 25.4, 16.2. HRMS (ESI+, m/z): Calcd for C18H25O6 [M + H+]: 337.1643, found: 337.1646.
:
1) afforded 5a (197.9 mg, 68%) as a colorless oil. [α]20D = −2.4° (c = 1.0 in CHCl3). 1H NMR (400 MHz, CDCl3): δ 6.89–6.83 (m, 2H), 6.83–6.77 (m, 2H), 5.86 (ddd, J = 6.3, 10.7, 17.2 Hz, 1H), 5.31 (dd, J = 8.8, 14.0 Hz, 2H), 4.79 (dd, J = 4.8, 5.7 Hz, 1H), 4.06–3.98 (m, 2H), 3.76 (s, 3H), 3.72–3.65 (m, 1H), 2.27–2.15 (m, 1H), 1.41 (s, 3H), 1.36 (s, 3H), 0.93 (d, J = 6.9 Hz, 3H). 13C NMR (101 MHz, CDCl3): δ 153.8, 152.1, 134.8, 118.1, 117.1, 114.4, 108.6, 80.0, 76.6, 67.6, 55.7, 40.6, 26.7, 25.7, 10.1. HRMS (ESI+, m/z): Calcd for C17H25O4 [M + H+]: 293.1745, found: 293.1747.
:
1) afforded 5b (217.2 mg, 74%) as a pale yellow oil. [α]20D = −2.8° (c = 1.0 in CHCl3). 1H NMR (400 MHz, CDCl3): δ 6.91–6.76 (m, 4H), 5.84 (ddd, J = 17.3, 10.7, 5.3 Hz, 1H), 5.27–5.20 (m, 2H), 4.85–4.81 (m, 1H), 4.17 (td, J = 7.9, 6.1 Hz, 1H), 4.02 (dd, J = 8.0, 6.0 Hz, 1H), 3.76 (s, 3H), 3.67 (t, J = 7.9 Hz, 1H), 1.95–1.86 (m, 1H), 1.41 (s, 3H), 1.32 (s, 3H), 0.96 (d, J = 7.0 Hz, 3H). 13C NMR (101 MHz, CDCl3): δ 153.9, 152.8, 136.8, 117.4, 116.6, 114.4, 108.5, 79.4, 77.0, 67.7, 55.7, 42.1, 26.7, 25.7, 8.7. HRMS (ESI+, m/z): Calcd for C17H25O4 [M + H+]: 293.1747, found: 293.1748.
:
1) afforded 5c (38.9 mg, 67%) as a colorless oil. [α]20D = +7.2° (c = 1.0 in CHCl3). 1H NMR (400 MHz, CDCl3): δ 6.84–6.77 (m, 4H), 5.89–5.79 (m, 1H), 5.29–5.22 (m, 2H), 4.50 (t, J = 5.1 Hz, 1H), 4.13 (dd, J = 13.8, 6.8 Hz, 1H), 4.04 (dd, J = 8.1, 6.0 Hz, 1H), 3.76 (t, J = 8 Hz, 1H), 3.75 (s, 3H), 2.03–1.95 (m, 1H), 1.37 (s, 3H), 1.35 (s, 3H), 1.13 (d, J = 6.9 Hz, 3H). 13C NMR (101 MHz, CDCl3): δ 153.9, 152.1, 135.7, 117.7, 117.0, 114.5, 105.3, 80.9, 77.1, 68.0, 55.6, 41.1, 26.6, 25.7, 11.4. HRMS (ESI+, m/z): Calcd for C17H25O4 [M + H+]: 293.1747, found: 293.1748.
:
1) afforded 7a (130.6 mg, 56%) as a pale yellow oil. [α]20D = +9.0° (c = 1.0 in CHCl3). 1H NMR (400 MHz, CDCl3): δ 6.86–6.78 (m, 4H), 6.00 (dt, J = 15.1, 7.5 Hz, 1H), 5.83 (dd, J = 15.4, 6.3 Hz, 1H), 4.87–4.83 (m, 1H), 4.04 (dd, J = 7.8, 6.0 Hz, 1H), 3.99–3.92 (m, 2H), 3.76 (s, 3H), 3.65 (dd, J = 9.9, 5.5 Hz, 1H), 2.26–2.17 (m, 1H), 1.41 (s, 3H), 1.37 (s, 3H), 0.92 (d, J = 6.9 Hz, 3H). 13C NMR (101 MHz, CDCl3): δ 154.0, 151.8, 132.0, 129.6, 117.1, 114.5, 108.8, 78.4, 76.6, 67.9, 55.7, 41.1, 31.8, 26.8, 25.7, 10.1. HRMS (ESI+, m/z): Calcd for C18H26BrO4 [M + H+]: 385.1009, found: 385.1002.
:
1) afforded 7b (114.9 mg, 54%) as a pale yellow oil. [α]20D = −22.0° (c = 1.0 in CHCl3). 1H NMR (400 MHz, CDCl3): δ 6.89–6.77 (m, 1H), 5.90 (dt, J = 7.3, 6.8 Hz, 1H), 5.79 (dd, J = 15.4, 5.0 Hz, 1H), 4.89–4.86 (m, 1H), 4.14 (dt, J = 14.1, 7.1 Hz, 1H), 4.02 (dd, J = 8.0, 6.0 Hz, 1H), 3.95 (d, J = 7.3 Hz, 1H), 3.76 (s, 3H), 3.65 (t, J = 7.8 Hz, 1H), 1.93–1.84 (m, 1H), 1.41 (s, 3H), 1.31 (s, 3H), 0.95 (d, J = 7.0 Hz, 3H). 13C NMR (101 MHz, CDCl3): δ 154.1, 152.5, 134.1, 128.2, 117.4, 114.5, 108.6, 78.0, 76.9, 67.8, 55.7, 42.2, 31.9, 26.9, 25.7, 8.9. HRMS (ESI+, m/z): Calcd for C18H26BrO4 [M + H+]: 385.1009, found: 385.1002.
:
1) afforded 8a (48.9 mg, 77%) as a colorless oil. [α]20D = +23.4° (c = 1.0 in CHCl3). 1H NMR (400 MHz, CDCl3): δ 6.88–6.77 (m, 4H), 6.01–5.91 (m, 1H), 5.07 (d, J = 16.9 Hz, 1H), 5.01 (dd, J = 10.3, 1.0 Hz, 1H), 4.31 (dd, J = 13.9, 6.3 Hz, 1H), 4.08 (t, J = 5.2 Hz, 1H), 3.89 (dd, J = 8.1, 6.3 Hz, 1H), 3.76 (s, 3H), 3.63 (t, J = 7.9 Hz, 1H), 2.73–2.63 (m, 1H), 2.34–2.24 (m, 1H), 1.40 (s, 3H), 1.34 (s, 3H), 1.11 (d, J = 6.9 Hz, 3H), 0.92 (d, J = 7.0 Hz, 3H). 13C NMR (101 MHz, CDCl3): δ 153.6, 153.5, 140.7, 116.6, 114.7, 114.6 (2×), 108.2, 83.5, 76.1, 66.6, 56.7, 40.3, 38.2, 26.5, 25.4, 17.9, 11.3. HRMS (ESI+, m/z): Calcd for C19H28O4Na [M + Na+]: 343.1880, found: 343.1880.
:
1) afforded 8b (48.9 mg, 77%) as a colorless oil. [α]20D = +2.2° (c = 1.0 in CHCl3). 1H NMR (400 MHz, CDCl3): δ 6.98–6.92 (m, 2H), 6.79–6.74 (m, 2H), 5.80 (ddd, J = 17.6, 10.3, 7.5 Hz, 1H), 5.06 (dd, J = 17.2, 1.2 Hz, 1H), 4.93 (d, J = 10.3 Hz, 1H), 4.34 (dd, J = 8.3, 1.8 Hz, 1H), 3.99–3.91 (m, 2H), 3.75 (s, 3H), 3.58–3.52 (m, 1H), 2.63–2.53 (m, 1H), 2.00–1.91 (m, 1H), 1.40 (s, 3H), 1.24 (s, 3H), 1.02 (d, J = 6.9 Hz, 3H), 0.94 (d, J = 6.9, 3H). 13C NMR (101 MHz, CDCl3): δ 154.3, 153.4, 141.4, 117.2, 114.5, 114.3, 108.6, 81.8, 77.2, 68.5, 55.7, 40.8, 39.3, 27.0, 25.6, 16.6, 9.1. HRMS (ESI+, m/z): Calcd for C19H28O4Na [M + Na+]: 343.1880, found: 343.1879.
:
1) afforded 8c (17.9 mg, 50%) as a colorless oil. [α]20D = −2.4° (c = 1.0 in CHCl3). 1H NMR (400 MHz, CDCl3): δ 6.90–6.83 (m, 2H), 6.82–6.77 (m, 2H), 5.82 (ddd, J = 17.4, 10.2, 8.6 Hz, 1H), 5.12 (dd, J = 17.6, 1.6 Hz, 1H), 5.03 (dd, J = 10.3, 1.7 Hz, 1H), 4.30 (q, J = 7.1 Hz, 1H), 4.14 (dd, J = 8.2, 3.4 Hz, 1H), 3.95 (dd, J = 8.1, 6.1 Hz, 1H), 3.76 (s, 2H), 3.58 (t, J = 8.0 Hz, 1H), 2.69 (h, J = 7.2 Hz, 1H), 2.25 (td, J = 7.0, 3.4 Hz, 1H), 1.40 (s, 3H), 1.36 (s, 3H), 1.09 (d, J = 6.7 Hz, 3H), 0.92 (d, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3): δ 153.6, 153.4, 141.1, 116.5, 115.0, 114.6, 108.2, 82.8, 76.1, 67.4, 55.7, 41.0, 38.6, 26.5, 25.6, 17.7, 11.3. HRMS (ESI+, m/z): Calcd for C19H28O4Na [M + Na+]: 343.1880, found: 343.1881.
:
1) to afford syn-11a (23%, 10.5 mg) as a colorless oil. [α]20D = +6.8° (c = 0.5 in CHCl3) 1H NMR (400 MHz, CDCl3) δ 7.76–7.67 (m, 4H), 7.44–7.33 (m, 6H), 5.85 (ddd, J = 17.0, 10.5, 9.1 Hz, 1H), 5.04–4.92 (m, 2H), 3.79–3.70 (m, 2H), 3.54–3.48 (m, 1H), 3.36 (dd, J = 10.4, 2.1 Hz, 1H), 2.46–2.36 (m, 1H), 1.67 (ddd, J = 16.9, 6.6, 3.8 Hz, 1H), 1.38 (s, 6H), 1.06 (d, J = 6.1 Hz, 3H), 1.05 (s, 9H), 0.70 (d, J = 6.6 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 139.9, 135.8, 129.4, 127.5, 114.7, 112.9, 97.6, 75.4, 65.7, 39.5, 32.0, 29.9, 26.8, 19.4, 19.3, 18.0, 11.5. HRMS (ESI+, m/z): Calcd for C28H40O3SiNa [M + Na+]: 475.2639, found: 475.2630.
Footnotes |
| † Dedicated to Prof. Barry Trost on the occasion of his 75th birthday. |
| ‡ Electronic supplementary information (ESI) available: Optimization studies, full experimental procedures and 1H and 13C NMR spectra of new compounds. See DOI: 10.1039/c6qo00199h |
| § Present address: Center for Research in Biological Chemistry and Molecular Materials (CIQUS) and Department of Organic Chemistry, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain. E-mail: E-mail: martin.fananas@usc.es |
| This journal is © the Partner Organisations 2016 |